Michigan Medicine, Ann Arbor, MI

Is Michigan Medicine registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Michigan Medicine hold a Michigan pharmacy license?

No license with this exact name and city was found in the Michigan Department of Licensing and Regulatory Affairs file dated Nov 10, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The list covers active licenses only. The file does list Michigan Medicine West Ann Arbor Health Center, Ann Arbor, a close but not exact match shown below.

Has Michigan Medicine had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Jun 13, 2019), 1 state referral letter (Jun 13, 2019) and 1 FMD-145 letter (Jun 13, 2019) for Michigan Medicine. Michigan board disciplinary actions: not checked, because the Michigan Department of Licensing and Regulatory Affairs data this index reads gives license status only and does not include disciplinary actions. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Michigan Medicine
Location
Ann Arbor, MI
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
0
Warning letters on FDA’s actions page
0
Latest action on that page
Jun 13, 2019
FDA Data Dashboard inspections
1 inspection: 1 OAI; 2 published Form 483s
Form 483 text on this page
2 Form 483s, 13 observations
State board records
No exact match

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Michigan Medicine, a 503A facility, with 3 dated actions.

Document
Jun 13, 2019Warning letter close-outWarning Letter Close Out Issued 06/13/2019Not linked by FDA
Jun 13, 2019FMD-145 letterFMD-145 Letter Issued 06/13/2019fda.gov
Jun 13, 2019State referral letterReferral Letter to the Michigan State Board of Pharmacy Issued 06/13/2019FDA copy (archived)

An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Michigan Medicine, Ann Arbor, MI (FEI number 3003531601), matched to this page by exact name, city and state. It lists 1 inspection: 1 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Jun 29, 2016Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3003531601991425

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 13 numbered observations in all, across 2 inspections ending Jun 29, 2016 to Dec 14, 2018. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Dec 3, 2018 to Dec 14, 2018: 5 observations

Firm on the cover
, Produc er o f Steril e and Non- Steril e Drug Produc t s 1bis document lists observations made by the FDA representative( ) during the inspection ofyow- facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement cotTective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this infonnation to FDA at the address above. If you have any questions, please contact FDA at the phone nwnber and address above.
FEI number
3003531601
FDA district office on the cover
Detro it, MI 48207
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Materials or supplies were not disinfected prior to entering the aseptic processing areas.

Specifically,

Product labels are printed in the unclassified area and transferred into the ISO 7 buffer room through the redacted b4. The labels are not sanitized or disinfected and are brought directly into the ISO 5 hood to label the product as was observed on 12/3/18 in redacted b4 for Leucovorin Dextrose 5% for Order redacted b46. On 12/6/18, I observed the labels that were printed in the unclassified area to touch the floor after they came out of the printer. These labels were brought into the ISO 7 buffer room without any sanitization.

On 12/3/18, I observed a sharpie-type pen being used in the ISO 5 hood #1 in redacted b4 to wri te on the product labels. Your firm stated that these pens are sanitized prior to entering the hoo ds, however, the pens are opened inside the hood and the pen tip is exposed to the IS O 5 environment. These pens remain inside the ISO 5 hood until they run out of ink.

Observation 2

Personnel moved rapidly in the vicinity of instrnments, which disrnpted the airflow and increased the risk ofbringing lesser quality air into the ISO 5 classified aseptic processing area.

Observation 3

Personnel engaged in aseptic processing were observed with exposed hands, exposed wrists, exposed legs, exposed hair and exposed mouth.

Specifically,

on 12/3/18, technicians working in redacted b4 were observed with exposed with exposed skin on t heir face, neck, and foreheads. Also, on 12/6/18, a technician wo rking in hood #1 in redacted b4 had exposed skin on their forehead and was observed with their head inside the iso 5 hood whil e processing sodium chloride dextrose 1 5% for order redacted b6. This same technician was also observed to rest their elbow of their non-sterile gown and have their sleeve touch the work surface.

Observation 4

Your facility was designed and/or operated in a way that perm.its poor flow of mate1ials.

Specifically,

Materials, including sterile drug products and components, are brought into the iso 7 buffer room directly from an unclassified area through a redacte d b4 in both redacted b4 and redacted b4

Observation 5

2. Cleaning is not adequately documented on the daily cleaning log. For example, the cleaning

agent used to clean the ISO 5 hood in B2 was not always documented in June 2018. Also, a s poricidal agent was not documented as being used to clean the iso 5 hood in b2 in July 2018 un til the 20th day of the month. The cleaning log states that a sporicidal agent should be used redacted b4.Cl eaning is not adequately documented on the daily cleaning log. For example, the cleaning agent used to clean the ISO 5 hood in B2 was not always documented in June 2018. Also, a sporicidal agent was not documented as being used to clean the iso 5 hood in b2 in July 2018 until the 20th day of the month. The cleaning log states that a sporicidal agent should be used redacted b4. Cleaning is not adequately documented on the daily cleaning log. For example, the cleaning agent used to clean the ISO 5 hood in B2 was not always documented in June 2018. Also, a sporicidal agent was not documented as being used to clean the iso 5 hood in b2 in July 2018 until the 20th day of the month. The cleaning log states that a sporicidal agent should be used redacted b4.

Inspection Jun 6, 2016 to Jun 29, 2016: 8 observations

Firm on the cover
, 1500 E . M e d i ca l Cente r Dr Univers ity Of Mic higa n, Ann Arbor, MI 48109-5000
FEI number
3003531601
Establishment type on the cover
Producer of Steri le Drug Produ c ts
FDA district office on the cover
300 River Place, Suite 5900, Detroit, MI 48207;
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Investigations of a failure of a batch or any of its components to meet any of its specifications did not extend to other batches of the same drug product and other drug products that may have been associated with the specific failure or discrepancy.

Specifically,

Review of multiple positive sterility test results and associated documentation noted that the investigations were inadequate regarding root cause identification, potential additional product or process impact evaluation, and corrective action.

i. Bupivacaine 0.125% epidural cassettes Print # REDACTED (b)(4) with REDACTED (b)(4) nits produced on 5/7/16 with expiry 6/6/16 and recovery of gram positive rods.

ii. Phenylephrine 1mg/10mL syringes Print # REDACTED (b)(4) with REDACTED (b)(4) units produced on 3/30/16 with expiry 4/29/16 and recovery of coagulase negative Staphylococcus species. f{tiiii]

... f{tiiii] iii. Calcium Gluconate 1g/50mL IV Bags Print with# REDACTED (b)(4) units produced on 3/2/16 with expiry 4/l/16 and recovery of gram negative rods and coagulase negative Staphylococcus species.

iv. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not written and followed.

Specifically,

A. The aseptic practices and techniques observed at facility during aseptic process of sterile drug products are inadequate. On 6/6/16 in Cleanrooms REDACTED (b)(4) and on 6/7/16 in Cleanroom REDACTED (b)(4) the following were observed:

i. Items such as wrapped syringes, a plastic tub, vials, and IV bags were transferred from the ISO 7 space to the ISO 5 work area without sanitization.

ii. Non-sterile gauze wipes were placed directly in the ISO 5 hoods.

iii. Operators were observed to contact items within the ISO 5 hoods without sanitizing their gloved hands after contacting items and surfaces in the ISO 7 area.

iv . Operators were observed to rest their gloved hands and non-sterile gown sleeves on the ISO 5 work surface. v. Bottles of sterile REDACTED (b)(4) are hung on the trash can lip in the ISO 7 space. These spray bottles are used for surface and glove sanitization in the ISO 5 work area. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.

Specifically,

A. Surfaces in the ISO 5 hoods included cracks and seams that are not easily cleanable. For example, Hood REDACTED B4 in REDACTED B4 was observed with a small open seam where the work surface and right wall connect. These services are not easily cleanable. Processing of Calcium Chloride 10% injectable Print IGDIII] was observed in Hood REDACTED (b)(4) 6/7/16.

B. During aseptic processing in the ISO 7 Cleanroom on REDACTED (b)(4) on REDACTED (b)(4) the following was observed.

i. At least one ceiling tile was not secure to its frame approximately half an inch when the door opened and closed.

ii. The smooth sprinkler covers were not flush with the ceiling tiles with rough edges of the cut ceiling tile visible. These gaps to the unclassified space above the cleanroom were not sealed. iii. Surface damage, including small gouges and peeling, was observed on multiple cleanable surface. iii. Surface damage, including small gouges and peeling, was observed on multiple cleanable surface. iii. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.

Specifically,

Non-sterile wipes are routinely used in cleanrooms REDACTED (b)(4) on the ISO 5 work surfaces. For example, nonsterile wipes sprayed with sterile REDACTED (b)(4) are used in the following instances:

i. To periodically sanitize the ISO 5 work surface during sterile drug processing activities.

ii. To remove REDACTED (b)(4) residues from the ISO 5 work surfaces after use of REDACTED (b)(4) wipes which are applied REDACTED (b)( 4).

For example, on 6/7/16, REDACTED (b)(4) Cefazolin 10gm syringes Print # REDACTED (b)(4) and REDACTED (b)(4) mini-bags in cleanroom REDACTED (b)(4) hood REDACTED (b)(4) an operator was observed to sanitize the interior ISO 5 hood work surface with a non-sterile wipe sprayed with sterile REDACTED (b)(4).

Observation 5

Clothing of personnel engaged in the processing of drug products is not appropriate for the duties they perform.

Specifically,

Gowning components such as the face mask, shoe covers, and hair net donned by aseptic processing personnel for use in are non-sterile. The current gowning method of operators performing aseptic operations provides incomplete coverage with exposure of facial and neck skin. The gown used by operators extends down to knee height only and is open in the back exposing the hospital scrubs which are worn in unclassified areas to the cleanroom environment.

For example, aseptic p rocessing of Calcium Chloride 10% Print # REDACTED (b)(4) and Cefazolin 10 gm syringes Print # REDACTED (b)(4) was observed on 6/7/16 in REDACTED (b)(4).

Observation 6

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

A. The environmental and personnel monitoring program for your facility cleanrooms REDACTED (b)(4) is inadequate in that:

V

iable environmental mo nitoring is not performed during each productio n shift in the critical a reas. Active viable air sa

i.

mple s are taken in the REDACTED (b)(4 ) approximately every REDACTED (b)(4). ii. Viab le surface monitoring is not performed during each production shift in c ritical

areas such as the ISO 5 work surfaces. Surface samples are collected approximately every REDACTED (b)(4) in the REDACTED (b)(4). Iii. Non-viable particulate (NVP) monitoring is not performed during each drug production shift in the critical areas. NVP monitoring is performed approximately every REDACTED (b)(4) of the REDACTED (b)(4).

B. Adequate investigations including root cause assessment, product and process impact, and associated corrective and preventative actions were not conducted for the following environmental monitoring results: ...

Read the full 483 (PDF on fda.gov)

Observation 7

Each batch of drug product purporting to be sterile is not laboratory tested to determine conformance to such requirements.

Specifically,

D. No method suitability studies using the required organisms in the presence of product have been performed for any of the

tested formulations. E. There is inadequate justification for the sample size (minimum to be used for each medium quantity to be used for testing via the REDACTED (b)(4) method. For example, for Phenylephrine Print # REDACTED (b)(4) consisting of REDACTED (b)(4) units of 10 mL syringes,

Sterility testing is limited only to REDACTED (b)(4) what include, but are not limited to REDACTED (b)(4).

Observation 8

Drug product containers were not sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended use.

Specifically,

The in-process REDACTED (b)(4) used to formulate Calcium Chloride 10% for REDACTED (b)(4) are not approximately sterilized and depyrogenated prior to use. Currently these REDACTED (b)(4) are washed using REDACTED (b)(4) prior to use. For example, Calcium Chloride 10% Print # REDACTED (b)(4) processed on 6/7/16.

State board of pharmacy records

No license with this exact name and city was found in the Michigan Department of Licensing and Regulatory Affairs file dated Nov 10, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The list covers active licenses only. Board file.

What this covers: LARA’s list gives each license’s status in the department’s words but lists no disciplinary actions, and the department’s disciplinary action reports sit on its website, which refused this index’s automated requests, so Michigan board actions are not checked. The list covers active licenses only (including those the department marks as in late renewal or limited), so a pharmacy with no match may hold a license that is no longer active.

Close but not exact board records

These board records share a name with this pharmacy but did not meet this index’s matching rule (same name, same city, same state), so they are not treated as its license. They may belong to a separate business.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.